Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 7;11(4):198-202.
doi: 10.4103/gmit.gmit_95_21. eCollection 2022 Oct-Dec.

Ulipristal Acetate in Adenomyosis

Manuel Gonçalves-Henriques  1 , António de Pinho  2   3 , Marília Freixo  2 , Maria Liz-Coelho  2 , Fabiana Castro  2 , Nathan Ceschin  4   5 , Pedro Brandão  3   4
Affiliations
Review

Ulipristal Acetate in Adenomyosis

Manuel Gonçalves-Henriques et al. Gynecol Minim Invasive Ther. .

Abstract

Adenomyosis is defined as the invasion of the basal endometrium (stroma and glands) into the underlying myometrium. It may lead to abnormal uterine bleeding (AUB), pelvic pain, and infertility. The definitive treatment is hysterectomy. Some conservative measures have been used in patients willing to procreate. Ulipristal acetate is a selective progesterone receptor modulator used to treat AUB caused by leiomyomas. This is a systematic review on the use of ulipristal to treat adenomyosis. Eight eligible articles were retrieved from PubMed, SCOPUS, and Cochrane Library. Only one randomized clinical trial was published until date concerning this matter. It seems that ulipristal acetate induces partial or complete remission of AUB caused by adenomyosis, but the evidence concerning its effect on pelvic pain and the radiologic findings of the disease is conflicting. Nevertheless, given the paucity of data, it is still preliminary to draw any conclusion about the subject.

Keywords: Adenomyosis; infertility; progesterone; receptors; ulipristal acetate; uterine hemorrhage.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Flowchart 1
Flowchart 1
Flow diagram of study selection (according to PRISMA statement)
See this image and copyright information in PMC

References

    1. Dason ES, Chan C, Sobel M. Diagnosis and treatment of adenomyosis. CMAJ. 2021;193:E242.. - PMC - PubMed
    1. Brosens JJ, de Souza NM, Barker FG. Uterine junctional zone: Function and disease. Lancet. 1995;346:558–60. - PubMed
    1. Puente JM, Fabris A, Patel J, Patel A, Cerrillo M, Requena A, et al. Adenomyosis in infertile women: Prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol. 2016;14:60.. - PMC - PubMed
    1. Cozzolino M, Basile F, Pontrelli G. Effects of adenomyosis on obstetric outcomes. Minerva Ginecol. 2019;71:146–54. - PubMed
    1. Ferro J, Labarta E, Sanz C, Montoya P, Remohi J. Reproductive outcomes after hysteroscopic metroplasty for women with dysmorphic uterus and recurrent implantation failure. Facts Views Vis Obgyn. 2018;10:63–8. - PMC - PubMed